Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Rectal Cancer
Drug:
Zaltrap (ziv-aflibercept IV)
(
VEGF-A inhibitor
,
PIGF inhibitor
,
VEGF-B inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Rectal cancer: UNRESECTABLE METACHRONOUS METASTASES...Previous adjuvant FOLFOX/CAPEOX within past 12 months...(FOLFIRI or irinotecan) ± (bevacizumab [preferred] or ziv-aflibercept or ramucirumab)
Secondary therapy:
FOLFIRI; irinotecan
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login